Netherlands, Utrecht

Pharmacoeconomics

when 18 July 2016 - 22 July 2016
language English
duration 1 week
credits 1.5 ECTS
fee EUR 1150

Today' society is confronted with ever increasing health care costs. One of the factors is the cost of drug innovations. Diseases waiting for therapeutic solutions are complicated and multifactorial in nature. As a result, drug innovation has become even more complex leading to high tech and therefore high cost solutions. The question arises, what is the added value of such high cost innovations and how can it be determined when both benefit and harm are considered. Health economics, and more specific pharmacoeconomics, aims to provide a neutral scientific approach to this challenge.

This course aims to provide a broad perspective of the field, including a variety of subjects from views of the different stakeholders to more in depth methodological approaches, illustrated with examples and exercises.

You will experience an intensive programme covering the following topics: Pharmacoeconomic techniques; Study designs and methods; Critical appraisal of pharmacoeconomic studies; The (im)possibilities of the use of HTA and pharmacoeconomics in regulatory decisions; The economics of personalized medicine; Pharmacoeconomics of orphan drugs

Course leader

Dr. A.M. H?vels

Target group

(Post)graduates and professionals within governments, NGOs, industry, universities with a basic knowledge public health/medicine who have an interest in the policy aspects of pharmaceuticals, pharmacoepidemiology and/or pharmacoeconomics.

Course aim

This course aims to provide a broad perspective of the field, including a variety of subjects from views of the different stakeholders to more in depth methodological approaches, illustrated with examples and exercises.

Fee info

EUR 1150: Course + course materials + housing
EUR 950: Course + course materials

Register for this course
on course website